6 studies found for:    Pulmonary Arterial Hypertension Receiving UT-15C
Show Display Options
Rank Status Study
1 Recruiting Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: UT-15C (treprostinil diethanolamine);   Drug: Placebo
2 Active, not recruiting Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C SR
3 Completed
Has Results
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
Condition: Pulmonary Hypertension
Interventions: Drug: UT-15C SR;   Drug: Placebo
4 Completed
Has Results
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets;   Other: Placebo
5 Completed
Has Results
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets;   Drug: Placebo
6 Withdrawn FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: UT-15C 1 mg;   Drug: UT-15C 0.25 mg;   Drug: UT-15C 5 mg;   Drug: Placebo

Indicates status has not been verified in more than two years